Loading clinical trials...

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis

NCT06886009•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
•Patients with generalized pustular psoriasis (GPP) flare
•Age \>/=19 years at enrolment
•Patients who have signed the data release consent form

Exclusion Criteria

•Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
•Patients with clinically important active infections (e.g. active tuberculosis)

Locations (4)

Pusan National University Yangsan Hospital

Busan, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Ajou University Hospital

Suwon, South Korea

Key Dates

Start Date

March 31, 2026

Primary Completion Date

June 8, 2029

Completion Date

June 8, 2029

Last Updated

February 17, 2026

Enrollment

ESTIMATED participants

Conditions

Generalized Pustular Psoriasis

Interventions

Spevigo®

DRUG

Contacts

Boehringer Ingelheim

CONTACT

1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536

Generalized Pustular Psoriasis

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06323356

Generalized Pustular PsoriasisErythrodermic Psoriasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis Registry in Costa Rica

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis